Gastrointestinal Malignancy. Malignant neoplasm of ill-defined sites within the digestive system
Conditions
Interventions
Intervention 1: Intervention group: combined treatment with curcumin - patients who receive 80 mg of Curcumin Elixir Nano Sina capsules along with antidepressants from the SSRI group including fluoxet
Sponsors
Zahedan University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Men over 18 years old with gastrointestinal cancers At least 6 months have passed since the onset of the disease. They must meet the depression criteria according to DSM-5 criteria They must be willing to participate in the study. do not have any contraindications for prescribing curcumin. No previous use of pharmaceutical antidepressants, no use of cigarettes and curcumin supplements.
Exclusion criteria
Exclusion criteria: People who are in the end stage of cancer. Do not want to participate in the study. Do not have depression criteria. Patients under 18 years old Patients with panic disorder, bipolar disorder, co morbid obsessive-compulsive disorder, post traumatic stress disorder, eating disorder, or any substance abuse or dependence disorder and people at high risk of suicide. Patients with medical diseases such as diabetes, autoimmune diseases, cardiovascular diseases, high blood pressure, Alzheimer's disease, Parkinson's disease, stroke and multiple sclerosis, chronic fatigue syndrome, fibromyalgia and asthma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Depression. Timepoint: Before starting the intervention, after completing the treatment period. Method of measurement: Beck depression questionnaire.;Anxiety. Timepoint: Before starting the intervention, after completing the treatment period. Method of measurement: Beck's anxiety questionnaire.;Pain. Timepoint: Before starting the intervention, after completing the treatment period. Method of measurement: Pain Self-Efficacy Questionnaire.;BDNF. Timepoint: Before starting the intervention, after completing the treatment period. Method of measurement: ELISA method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Yalda Sargazi
Zahedan University of Medical Sciences
Outcome results
None listed